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We appreciate Dr. Griffiths and colleagues’ letter and their
interest in our paper (1). They raised quite an important fun-
damental issue regarding the cost-benefit analysis (CBA)
study. In CBA study, many assumptions are needed because
of the lack of baseline data, which are the main weakness of
this kind of study. We also did several assumptions, which
are not verified in other studies. Dr. Griffiths et al. pointed
out this. Therefore, the CBA study can be a reference in deci-
sion on health policy, especially when the policy on national
immunization, but many other discussions are also very im-
portant. 
First, Dr. Griffiths et al. mentioned the unreasonably high
price of the Hib vaccine in Korea in our study. It was one of
most serious difficulties when gathering information regard-
ing the vaccine price in the conduction of CBA. Thus far, the
Hib vaccine has not been included in the Korean universal
vaccination, and no data existed regarding the Hib vaccine.
Therefore, we went through the vaccine prices in private clin-
ics in 2003. The price of the Hib immunization is KRW
40,000, which includes the vaccine (around KRW27,000-
30,000) and administration (around KRW10,000). Based
on this data, it was assumed that there would be a 50% reduc-
tion in the administrative costs and a 20% reduction in the cost
of the Hib vaccine. Therefore, we used KRW26,000 per shot.
If the Hib immunization, however, was adopted in a nation-
al immunization schedule, the cost of the vaccine would prob-
ably be lower due to the economy of scale. Under another
scenario, applying US$9 or US$11 per dose as in US, the
benefit-cost ratio of Hib immunization in our paper (1) would
be increased to 1.52-1.86, and then we could expect the eco-
nomic efficiency to increase significantly. 
Second, Dr. Griffiths et al. pointed out the incidence data
of Hib infection in this study. The study by Kim et al. (2),
which was used to estimate the annual incidence in our study,
was the first population-based study and the only report of
annual incidence of Hib meningitis in Korea. However, this
study did not include Hib infection apart from Hib menin-
gitis. Unavoidably, we had to assume the incidence rate of
Hib pneumonia based on United States’ epidemiology data
(3). To estimate Hib pneumonia in Korea, the proportion of
meningitis and pneumonia in US was initially estimated,
and the rate was then applied to estimate Korean Hib pneu-
monia incidence. In addition, the trend of Korean Hib menin-
gitis is not equal to those of other Asian countries; therefore,
it is also difficult to assume that Hib pneumonia is more pre-
valent than Hib meningitis, as in Indonesia. Although a sensi-
tivity analysis was conducted to test uncertainty concerning
the incidence of Hib infection, we also recognize that a prob-
lem of estimation of the incidence based on other country’s
epidemiologic data exists.
We completely agree with Dr. Griffiths et al. last point.
Economic evaluation is just one method available to provide
information to help develop policy. Despite the low econom-
ic efficiency, we would like to point out that there are a sig-
nificant number of cases of disease, deaths and sequelae that can
be prevented by Hib vaccination. The scope of this study, how-
ever, was to test the efficiency of Hib universal immunization
based on a CBA. Except for the CBA, other discussions regard-
ing whether Hib vaccination should be included in the Kore-
an national vaccination program are beyond the scope of this
study; therefore, discussion on that point was not included. 
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